Spots Global Cancer Trial Database for Pembrolizumab in Refractory Advanced Esophageal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Pembrolizumab in Refractory Advanced Esophageal Cancer

Official Title: A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer

Study ID: NCT02971956

Conditions

Esophageal Cancer

Squamous Cell Esophagus Cancer

Adenocarcinoma Esophagus

Interventions

Pembrolizumab

Study Description

Brief Summary: This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab

Detailed Description: This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Pembrolizumab for the participant specific disease but it has been approved for other uses. Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other countries to treat other types of diseases. The goal of this research study is to -Evaluate the safety and efficacy of pembrolizumab in participants with advanced esophageal cancer that have not responded to standard treatment.